Prediction: Buying Pfizer Stock Today Could Set You Up for Life

Core Insights - Pfizer faced a significant setback by abandoning its internally developed GLP-1 weight loss drug in April 2025, falling behind competitors like Novo Nordisk and Eli Lilly in a growing market [1][2] - Despite recent challenges, including a 50% decline in stock value since 2021 and upcoming patent expirations, Pfizer quickly pivoted by acquiring a company with a promising GLP-1 candidate, closing the deal in November 2025 [3][4] - Pfizer maintains a market capitalization of $150 billion, indicating its status as a respected industry giant, even amidst fluctuations in the pharmaceutical sector [4][6] Financial Performance - Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, experienced remarkable revenue growth of 99% and 175% respectively in 2025, highlighting strong consumer demand in the GLP-1 market [2] - Pfizer's current stock price is $27.04, with a market cap of $154 billion, a gross margin of 66.23%, and a dividend yield of 6.36% [5][6] - The company has a payout ratio exceeding 100%, which may raise concerns for conservative dividend investors, yet management intends to maintain the dividend [7] Future Outlook - In February 2026, Pfizer announced progress on a long-acting GLP-1 drug, indicating that the company remains on track despite previous setbacks [6] - Long-term investors may find Pfizer appealing due to its industry leadership and potential for consistent dividends over time [7]